Cone Rod Dystrophy Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

The Cone Rod Dystrophy therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Cone rod dystrophies patients, the rise in the number of healthcare spending across the world, and the expected entry of emerging therapies in the market.

Key players, such as MeiraGTx, Applied Genetic Technologies Corp, and others are in the process of developing potential therapies for the treatment of Cone Dystrophy. The launch of emerging therapies is expected to significantly impact the treatment scenario of Cone rod dystrophies in the upcoming years.

"Cone Rod Dystrophy Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cone Rod Dystrophy Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Cone Rod Dystrophy Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Cone Rod Dystrophy Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cone Rod Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cone Rod Dystrophy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Cone Rod Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/cone-rod-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/cone-rod-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Leading Companies in the Cone Rod Dystrophy Therapeutics Market Include
• MeiraGTx
• Applied Genetic Technologies Corp
• Nightsta Therapeutics
And Many Others

Cone Rod Dystrophy Therapies Covered in the Report Include:
• AAV-RPGR - MeiraGTx is working on its lead candidate AAV-RPGR, designed to treat the most common form of X-linked retinitis pigmentosa (XLRP). In 2020, MeiraGTx announced six, nine, and 12-month results from the dose escalation phase of the Phase I/II trial, with data demonstrating statistically significant improvement in retinal sensitivity and vision-guided mobility. AAV-RPGR has received Fast Track and Orphan Drug designations from the FDA and Orphan Medicinal Product designation from the EMA.
• AGTC-501 - Applied Genetic Technologies Corp is evaluating AGTC-501, a recombinant adeno-associated virus vector, for the treatment of X-Linked Retinitis Pigmentosa. Curently this molecule is in Phase II/III stage.
• AAV8-RPGR - Nightstar Therapeutics was developing AAV8-RPGR, is a subretinal AAV-based Adeno-Associated Viral Vector Encoding RP GTPase Regulator gene therapy for trial for Nonsyndromic X-linked Retinitis Pigmentosa (XLRP). In 2019, Biogen acquire Nightstar Therapeutics. According to the Phase II/III results published by Biogen in 2021, the study did not meet its primary endpoint, but the data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual acuity, and the company is encouraged with this finding.

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Cone Rod Dystrophy Current Treatment Patterns
4. Cone Rod Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cone Rod Dystrophy Late-Stage Products (Phase-III)
7. Cone Rod Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cone Rod Dystrophy Discontinued Products
13. Cone Rod Dystrophy Product Profiles
14. Cone Rod Dystrophy Key Companies
15. Cone Rod Dystrophy Key Products
16. Dormant and Discontinued Products
17. Cone Rod Dystrophy Unmet Needs
18. Cone Rod Dystrophy Future Perspectives
19. Cone Rod Dystrophy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/cone-rod-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.